In December 2023, GP2 announced the sixth data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PD. This release includes >20,000 additional participants, adding to the previous releases from the Complex and Monogenic Networks. The complex disease data (genotypes), including locally-restricted samples, now consists of a total of 44,831 genotyped participants (24,709 PD cases, 17,246 Controls, and 2,876 ‘Other’ phenotypes) When removing the locally-restricted samples, these now consist of 33,436 (17,129 PD cases, 13,872 Controls, and 2,435 ‘Other’ phenotypes) The monogenic disease data (whole genome sequences) now consists of a total of 2,324 sequenced participants (1,854 PD cases, 314 Controls, and 156 ‘Other’ phenotypes) When removing the locally-restricted samples, these now consist of 2,083 (1,650 PD cases, 309 Controls, and 124 ‘Other’ phenotypes)12,585 individuals who have deep clinical phenotyping information also have matching genetic information Please see the accompanying blog for further description of this release. To obtain data access, please see https://amp-pd.org/researchers/data-use-agreement. For any publications using data from this release, please reference the DOI number and the following statement: "Data (DOI 10.5281/zenodo.10472143, release 6) used in the preparation of this article were obtained from the Global Parkinson’s Genetics Program (GP2)."